Raal et al. recognized that inclisiran powerfully and safely decreases the cholesterol levels among all cases of mild FH genotype carrying disease-causative polymorphisms, including LDLR, APOB, PCSK9, and LDLRAP1 [82]. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.